Abstract
The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.
Keywords: Rhenium-188, Copper-67, Bladder, Cancer, Radioimmunotherapy
Mini-Reviews in Medicinal Chemistry
Title: Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Volume: 4 Issue: 1
Author(s): M. Frier
Affiliation:
Keywords: Rhenium-188, Copper-67, Bladder, Cancer, Radioimmunotherapy
Abstract: The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.
Export Options
About this article
Cite this article as:
M. Frier , Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer, Mini-Reviews in Medicinal Chemistry 2004; 4 (1) . https://dx.doi.org/10.2174/1389557043487510
DOI https://dx.doi.org/10.2174/1389557043487510 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets The Regulatory Role of Both MBNL1 and MBNL1-AS1 in Several Common Cancers
Current Pharmaceutical Design Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets The First Total Synthesis of Tarennane, a Potent Antioxidant Chalcone Constituent from Tarenna Attenuate or Magnolia Officinalis
Letters in Organic Chemistry Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Current Drug Delivery ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Targeted Tumor Therapies at a Glance
Current Drug Targets A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines
Anti-Cancer Agents in Medicinal Chemistry New Antimicrobial Frontiers
Mini-Reviews in Medicinal Chemistry Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry MR Imaging Findings of Uterine Cervical Carcinoma
Current Medical Imaging Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine Targeting Bacterial Secretion Systems: Benefits of Disarmament in the Microcosm
Infectious Disorders - Drug Targets Systemic Delivery and Quantification of Unformulated Interfering RNAs In Vivo
Current Topics in Medicinal Chemistry Imaging Cellular Receptors in Breast Cancers: An Overview
Current Pharmaceutical Biotechnology Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry